Page 3,329«..1020..3,3283,3293,3303,331..3,3403,350..»

Category Archives: Transhuman News

Less effective DNA repair process takes over as mice age

Posted: September 9, 2014 at 7:57 pm

PUBLIC RELEASE DATE:

9-Sep-2014

Contact: Peter Iglinski peter.iglinski@rochester.edu 585-273-4726 University of Rochester http://www.twitter.com/UofR

As we and other vertebrates age, our DNA accumulates mutations and becomes rearranged, which may result in a variety of age-related illnesses, including cancers. Biologists Vera Gorbunova and Andei Seluanov have now discovered one reason for the increasing DNA damage: the primary repair process begins to fail with increasing age and is replaced by one that is less accurate.

The findings have been published in the journal PLOS Genetics.

"Scientists have had limited tools to accurately study how DNA repair changes with age," said Gorbunova. "We are now able to measure the efficiency with which cells in mice of different ages repair DNA breaks at the same place in the chromosome."

Gorbunova explained that when mice are young, the breaks in DNA strands are repaired through a process called non-homologous end joining (NHEJ), in which the damage is repaired by gluing the DNA together with no or very little overlap. However, Gorbunova and Seluanov found that NHEJ began to fail as the mice got older, allowing a less reliable DNA repair processmicrohomology-mediated end joining (MMEJ)to take over. With MMEJ repairs, broken ends are glued together by overlapping similar sequences that are found within the broken DNA ends. This process leads to loss of DNA segments and the wrong pieces being stitched together.

Gorbunova and her team were able to make their observations by working with genetically-modified mice whose cells produce green fluorescent protein (GFP) that glows each time the breaks are repaired. By tracking how many cells glowed green in different tissues, the researchers determined the efficiency of repair.

"We showed two things with these genetically-modified mice," said Gorbunova. "Not only did the efficiency of DNA repair decline with age, but the mice began using a sloppier repair mechanism, leading to more mutations, particularly in the heart and lungs."

DNA breaks occur frequently because animal cells are under constant assault from routine activities in the environmentwhether by a blast of X-rays from a visit to the doctor or simply breathing in oxygenand, as a result, the DNA molecules often get damaged.

See original here:
Less effective DNA repair process takes over as mice age

Posted in DNA | Comments Off on Less effective DNA repair process takes over as mice age

WorldViews: Author claims to have identified Jack the Ripper via DNA testing of a shawl

Posted: at 7:57 pm

In the end, it may have takena Johnny Depp movie, a shawl and a DNA testto solvethe mystery behind one of the most notorious serial killing sprees in London: Who was Jack the Ripper?

British businessman and noted "Ripperologist" Russell Edwards claims to havefinally and conclusively identified the serial killer asAaronKosminski, a Polish immigrant and barber.

Edwards unmasked his candidate for Jack the Ripper in the Daily Mail and chronicles how he came to the conclusion in a forthcoming book.

Kosminski has long been one of the more credible suspectsin thefivegruesome murders of women in the London's East End in 1888. Born in central Poland on Sept. 11, 1865, he moved with his family movedto east London in the early 1880s, and lived near the murder scenes, according to Agence France Presse.

He ended up in a workhouse the year after the murders and was described as destitute; a year later, he was discharged but eventually ended up in an insane asylum -- he was thought to have been "seriously mentally ill," Edwards writes -- where he died from gangrene in 1919. A witness had identified Kosminski as the murderer at the time.

Edwards said his interest in Jack the Ripper began after he watched"From Hell," a2001 film about the murders that starred Depp as a clairvoyant police inspector.

In 2007, Edwards bought a shawl thathad been discovered at the scene of the murder of Catherine Eddowes, the fourth Ripper victim. Before Edwards bought it, the shawl belonged to the relative of a police official who had been allowed to take it home to his dressmaker wife, Edwards writes. "Incredibly, it was stowed without ever being washed," and handed down in the family, he said.

When Edwards bought the shawl, he subjected it to DNA testing, which confirmed that the blood on it belonged to Eddowes. A UV light showed semen on the fabric. That DNA was compared to that of a Kosminski descendant, Edwards writes.

The identity of Jack the Ripper haseluded Brits for over a century and obsessedeveryone from serious academics to armchair detectives. Queen Victoria's grandson Prince Albert Victor was thought to be a suspectat one point, but it turned out he wasn't near the murders at the time. Other suspects have includedMary Pearcey ("Jill the Ripper"), who had been convicted of murdering her lover's wife; in 2006, an Australian scientist, pointing to DNA results, suggested the killer may have been a woman.

Historian Mei Trow had previously identified mortuary attendant Robert Mann as Jack the Ripper, using "psychological and geographical profiling," the Daily Mail wrote in 2009.The murdervictims' bodies would have been delivered to the mortuary where Mann worked, where he was suspected to have "admire[d] his handiwork."

Go here to see the original:
WorldViews: Author claims to have identified Jack the Ripper via DNA testing of a shawl

Posted in DNA | Comments Off on WorldViews: Author claims to have identified Jack the Ripper via DNA testing of a shawl

1. UCSC Genome Browser Tutorial: the basics – Video

Posted: at 7:57 pm


1. UCSC Genome Browser Tutorial: the basics
UCSC Genome Browser Tutorial Video 1 An introduction to the UCSC Genome Browser, a tool used by researchers around the world. Here I discuss: --genomes and assemblies --chromosome coordinates...

By: Sam Allon

See the article here:
1. UCSC Genome Browser Tutorial: the basics - Video

Posted in Genome | Comments Off on 1. UCSC Genome Browser Tutorial: the basics – Video

Uber vs. the Law (My Money's on Uber)

Posted: at 7:57 pm

I love Uber, the ridesharing app that connects people who need rides with drivers.Instead of my normal $35 taxi ride to LAX, an UberX car takes me for about $11.The service is active in 108 US cities and 45 countries worldwide.Five years ago, it didnt exist. Today, its valued at over $18 billion.It truly is an Exponential Organization.

Uber is one of a new generation of dematerializing, demonetizing and democratizing technologies thats disrupting the status quo.Simply put, Uber is a product adored by passengers and Uber drivers alike.It uses technology to dramatically improve a broken system. It solves a pain point.As a result,hordes have leftthe traditional taxis and rental car options.Understandably, these incumbents arent happy, and where do they turn?

Regulation.

Ubers Long, Legal Battle

I recently spent a week with Uber CEO Travis Kalanick in Sicily at Google Google Camp.Id heard mention of some of the legislative challenges that Uber was facing globally, but I wasnt really aware of the scope or scale of what was happening.

Check out this global resistance:

And yet:

Regulation, the Protection of Last Resort

Laws typically favor the incumbent solutions that manifested them in the first place.But when an industry turns to protectionist regulations to keep a more cost-effective solution out of the market, you know its in a death spiral.Take the horse versus the automobiles, for example. Many hated cars in the early 1900s because, well, they scared horses.In fact, amazingly, at the turn of the century, a law in Pennsylvania stated:

Any motorist who sights a team of horses coming toward him must pull well off the road, cover his car with a blanket or canvas that blends with the countryside, and let the horses pass. If the horses appear skittish, the motorist must take his car apart, piece by piece, and hide it under the nearest bushes.

View original post here:
Uber vs. the Law (My Money's on Uber)

Posted in Human Longevity | Comments Off on Uber vs. the Law (My Money's on Uber)

84 Psoriasis Cure Homeopathy Dr M N Raju 1 – Video

Posted: at 7:56 pm


84 Psoriasis Cure Homeopathy Dr M N Raju 1
First Health Channel in Telugu.

By: tv7healthplanet

See the rest here:
84 Psoriasis Cure Homeopathy Dr M N Raju 1 - Video

Posted in Psoriasis | Comments Off on 84 Psoriasis Cure Homeopathy Dr M N Raju 1 – Video

Psoriasis Nails Natural Treatment – Video

Posted: at 7:56 pm


Psoriasis Nails Natural Treatment
http://bit.ly/1lz8CvE Click this link find out about getting rid of psoriasis totally in under a week. This technique is quick and simple and actually is successful! Psoriasis nails natural...

By: Wanetta Durnell

Follow this link:
Psoriasis Nails Natural Treatment - Video

Posted in Psoriasis | Comments Off on Psoriasis Nails Natural Treatment – Video

My Psoriasis Journey – Video

Posted: at 7:56 pm


My Psoriasis Journey
Part One of a series of video interviews in which individuals talk about their condition. My Psoriasis Journey: Participants talk about their initial experiences and coping strategies after...

By: 8591DAC

See more here:
My Psoriasis Journey - Video

Posted in Psoriasis | Comments Off on My Psoriasis Journey – Video

Psoriasis Treatment Blog – Video

Posted: at 7:56 pm


Psoriasis Treatment Blog
http://bit.ly/1q9S4ua Click here find out about how to get rid of psoriasis for good in under three days. This method is quick and simple and really does the...

By: Rebeca Alphonse

Read this article:
Psoriasis Treatment Blog - Video

Posted in Psoriasis | Comments Off on Psoriasis Treatment Blog – Video

Psoriasis Treatment Choices Improving, FDA Says

Posted: at 7:56 pm

FRIDAY, Sept. 5, 2014 (HealthDay News) -- A growing knowledge of the skin disease called psoriasis is leading to greater treatment choices, including personalized therapies, the U.S. Food and Drug Administration reports.

Psoriasis is an immune system disorder that causes overproduction of skin cells, resulting in scaling, pain, swelling, redness and heat. The condition affects about 7.5 million Americans.

"As we better understand the disease, researchers know more about what specific factors to target in order to develop effective treatments," FDA dermatologist Dr. Melinda McCord said in an agency news release.

There is no cure for psoriasis, so the main goals of treatments are to stop skin cell overproduction and reduce inflammation. Current therapies include medicines applied to the skin (topical), light treatment (phototherapy), or drugs taken by mouth or given by injection.

Doctors used to take a step-by-step approach, starting patients with mild to moderate psoriasis on topical therapy. If that was ineffective, doctors moved on to phototherapy or drug treatment.

Treatment is now more patient-specific, with doctors and patients selecting a treatment based on its effectiveness, disease severity, lifestyle, risk factors and other health issues, according to the FDA.

"Tomorrow's treatments will become even more personalized because the drugs in development now are targeting different aspects of the immune system," McCord said.

"As we learn more about the immune pathways that lead to the development of psoriasis, we can target specific molecules for treatment and make more therapeutic options available to patients," she explained.

Patients need to educate themselves about their condition and treatment options.

"Psoriasis has a great emotional impact on some patients. But it doesn't have to, given the right care and treatment," McCord said.

Link:
Psoriasis Treatment Choices Improving, FDA Says

Posted in Psoriasis | Comments Off on Psoriasis Treatment Choices Improving, FDA Says

Penn researcher and CVS Health physician urge new payment model for gene therapy

Posted: at 7:56 pm

PUBLIC RELEASE DATE:

9-Sep-2014

Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine http://www.twitter.com/PennMedNews

PHILADELPHIA - Hoping to encourage sufficient investments by pharmaceutical companies in expensive gene therapies, which often consist of a single treatment, a Penn researcher and the chief medical officer of CVS Health outline an alternative payment model in this month's issue of Nature Biotechnology. They suggest annuity payments over a defined period of time and contingent on evidence that the treatment remains effective. The approach would replace the current practice of single, usually large, at-point-of-service payments.

"Unlike most rare disease treatments that can continue for decades, gene therapy is frequently administered only once, providing many years, even a lifetime, of benefit," says James M. Wilson, MD, PhD, professor of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania. "Under current reimbursement policies, private insurers and the government typically pay for this therapy once: when it is administered. But these individual payments could reach several million dollars each under current market conditions. We're proposing a different approach that spreads payments out and only keep coming if the patient continues to do well."

Wilson and co-author Troyen A. Brennan, MD, JD, MPH, chief medical officer of CVS Health, note that while large single payments for gene therapy may be the simplest approach, they carry substantial encumbrances. For example, approval of gene therapy treatments is unavoidably based on data derived from trials carried out over several years at most -- considerably shorter than the expected duration of the therapy. Payers may therefore be unwilling to pay large up-front sums for treatments whose long-term benefit has not been established. Additionally, large payments for medications, such as the $84,000-a-patient cost of the hepatitis C treatment Sovaldi, have been criticized in the prevailing climate of curbing health care costs. This, despite the fact that effective gene therapy may reduce the overall financial burden to the health care system.

Wilson and Brennan further note that while a liver transplant, for example, can cost up to $300,000, physicians and hospitals that "transplant livers know they will be compensated at market rates through existing contracts -- gene developers lack that assurance." Annuity payments, they say, could help address these problems.

An example of an annuity-type disbursement could be a hypothetical payment of $150,000 per year for a certain number of years for gene-therapy-based protein replacement for patients with hemophilia B -- so long as the therapy continues to work. According to the authors, the cumulative amount should be less than the cost of a one-time payment of $4-6 million, which would be the expected rate for a gene-based therapy to be comparatively priced to existing, conventional therapies for hemophilia B. "One would presume," they write, "that gene therapy will have to represent a discount in order for insurers to approve its use."

"The annuity model that we're proposing would eliminate the misguided incentive to invest in drugs and treatments with ongoing revenue streams but which require continuing, perhaps lifetime daily administration, with all the attendant inconveniences and burdens to patients and their families, as well as direct and indirect costs to the nation's health system," says Wilson.

The authors point out that gene therapy differs substantially from the case of "orphan" drugs. Development of the latter, which target rare diseases affecting small patient populations, is supported by the Orphan Drug Act of 1983, which provides pharmaceutical manufacturers with grants, tax credits, and an extended period of market exclusivity for their medications. What's more, in virtually all of these cases, the business costs of developing the drugs are further attenuated by ongoing administration of -- and payment for -- the medication over the lifetime of the patient. "The contrast with gene therapy, especially that which produces a durable cure with one administration," the authors write, "is clear."

View post:
Penn researcher and CVS Health physician urge new payment model for gene therapy

Posted in Gene Medicine | Comments Off on Penn researcher and CVS Health physician urge new payment model for gene therapy

Page 3,329«..1020..3,3283,3293,3303,331..3,3403,350..»